Section 3(d) for precluding patent evergreening: India's attempts to improve access to medicines
In the year 2013, India created a stir in the world of pharmaceutical patents by rejecting patent application of Novartis' anticancer drug, Glivec1. This rejection was based on section 3(d) of the Indian patent act2 which precludes evergreening of pharmaceutical patents yet claims to promote...
| Published in: | Интеллектуальные права: вызовы 21-го века : материалы Международной конференции (14-16 ноября 2019 г.) С. 133-139 |
|---|---|
| Main Author: | |
| Format: | Book Chapter |
| Language: | English |
| Subjects: | |
| Online Access: | http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000669793 Перейти в каталог НБ ТГУ |